SKYRIZI achieved blockbuster sales of $11.7 billion in 2024, growing 51% year-over-year, driven by approvals in psoriasis, psoriatic arthritis, and inflammatory bowel diseases like Crohn's. Its strong clinical efficacy targeting the IL-23 pathway and convenient dosing every 8-12 weeks support its market expansion. Positioned as a Humira replacement, SKYRIZI holds a dominant share in gastroenterology and is expected to continue growth with projected combined revenues with Rinvoq exceeding $31 billion by 2027. The drug's market outlook spans major regions including the US, EU4, UK, and Japan through 2034.
In June, biotech stocks propelled the ALPS Medical Breakthroughs ETF (SBIO) to an 18.7% return, its best month since December 2023. Major contributors included Apogee Therapeutics, which surged 61.6% following a $10.9 billion acquisition announcement...
AbbVie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio and prepare for upcoming patent expirations. AbbVie's existing drugs Skyrizi and Rinvoq have already surpassed Humira's peak sales and continue growing r...
In June 2026, biotechnology ETFs dominated the top performers, driven by AI advancements and increased mergers and acquisitions, with ARKG leading at a 24.15% return. Passive biotech ETFs like BBC, SBIO, and XBI also saw strong gains. Meanwhile, the ...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
US equity markets show signs of speculative excess with record margin debt at $1.4 trillion and leveraged ETF assets at $198 billion. The tech-heavy Nasdaq experienced its largest weekly drop since April 2025, reflecting a pullback in the most specul...
